Literature DB >> 22030990

Is the starting section for 3D volume acquisition in the first trimester relevant in the post hoc analysis of aneuploidy screening markers and fetal anatomy?

Antoni Borrell1, Joaquin Santolaya-Forgas, Cynthia Horbaczewski, Roshni Dorothy Henry, Lisa Dunn-Albanese, Julian N Robinson.   

Abstract

OBJECTIVE: To determine the ability to assess the fetal anatomy and ultrasound screening markers using three-dimensional (3D) volumes acquired during the 11th to 13th  week scan, in relation to whether a fetal profile could be used as a starting section.
METHODS: Post hoc analysis of 3D ultrasound volumes acquired at 11 to 13 weeks in 223 pregnancies was performed to identify the appropriate sections for evaluation of three screening markers and ten fetal anatomy landmarks. When possible, the fetal profile was used as the starting section for volume acquisition.
RESULTS: When the fetal profile was used, satisfactory images for assessment were obtained in 90% of cases for nuchal translucency and 72% for the nasal bone, whereas successful evaluation of the ten anatomical landmarks ranged from 0 to 99%. In alternative starting sections, the corresponding success rates were 65%, 48%, and 0-95%.
CONCLUSION: Although performance of post hoc analysis of 3D volumes is best when carried out from a profile starting section and quicker than two-dimensional analysis, it appears to be not ready for clinical use because nuchal translucency could not be examined in 10% of the fetuses.
Copyright © 2011 John Wiley & Sons, Ltd.

Mesh:

Year:  2011        PMID: 22030990     DOI: 10.1002/pd.2891

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  1 in total

1.  Clinical value of fetal facial profile markers during the first trimester.

Authors:  Xiaofeng Zhou; Chunya Ji; Lingling Sun; Linliang Yin; Xuedong Deng; Qi Pan; Jun Zhang; Zhong Yang; Chenhan Zheng; Chen Ling; Liping Shi; Yanqing Wu
Journal:  BMC Pregnancy Childbirth       Date:  2022-10-02       Impact factor: 3.105

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.